10:10:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-05-12 Ordinarie utdelning ATANA 0.00 SEK
2025-05-09 Kvartalsrapport 2025-Q1
2025-05-09 Årsstämma 2025
2025-02-21 Bokslutskommuniké 2024
2024-11-22 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-03 Kvartalsrapport 2024-Q1
2024-05-03 Årsstämma 2024
2024-02-23 Bokslutskommuniké 2023
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-08 Ordinarie utdelning ATANA 0.00 SEK
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 Årsstämma 2023
2023-02-24 Bokslutskommuniké 2022
2022-12-07 Extra Bolagsstämma 2022
2022-11-25 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-09 Ordinarie utdelning ATANA 0.00 SEK
2022-05-06 Kvartalsrapport 2022-Q1
2022-05-06 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-10 Ordinarie utdelning ATANA 0.00 SEK
2021-05-07 Kvartalsrapport 2021-Q1
2021-05-07 Årsstämma 2021
2021-02-25 Bokslutskommuniké 2020
2020-11-27 Kvartalsrapport 2020-Q3
2020-11-09 Extra Bolagsstämma 2020
2020-08-27 Kvartalsrapport 2020-Q2
2020-05-11 Ordinarie utdelning ATANA 0.00 SEK
2020-05-08 Kvartalsrapport 2020-Q1
2020-05-08 Årsstämma 2020
2020-02-24 Bokslutskommuniké 2019
2019-11-29 Kvartalsrapport 2019-Q3
2019-08-09 Extra Bolagsstämma 2019
2019-08-07 Kvartalsrapport 2019-Q2
2019-05-08 Ordinarie utdelning ATANA 0.00 SEK
2019-05-07 Kvartalsrapport 2019-Q1
2019-04-05 Årsstämma 2019
2019-02-26 Bokslutskommuniké 2018
2018-05-08 Ordinarie utdelning ATANA 0.00 SEK
2018-05-07 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017

Beskrivning

LandSverige
ListaNordic SME Sweden
SektorHälsovård
IndustriLäkemedel & Handel
Attana bedriver forskning och utveckling av läkemedel. Bolaget specialiserar sig inom biologisk interaktionskarakterisering, som används för analys i utvecklandet av nya läkemedel. Bolagets patenterade lösningar används vid studerandet av bindningsegenskaper och makrostrukturer i celler, proteiner, virus och bakterier. Verksamhet återfinns främst inom Norden och Europa. Bolaget grundades under 2002 och har sitt huvudkontor i Stockholm.
2021-01-14 08:10:00

Recently, an article about Attana's first non-clinical in vitro diagnostic (IVD) device, Attana Virus Analytics - AVA™, was published in IBI (International Biopharmaceutical Industry). The article explains how AVA could help provide invaluable insights when assessing patient immunity for SARS-CoV-2.

A brief summary of the article:

The Challenge of Assessing SARS-CoV-2 Immunity
One of the main challenges with SARS-CoV-2 is assessing patient immunity. Conventional testing methods focuse on the binary presence of virus-specific antibodies (e.g. IgA, IgM and IgG). However, SARS-CoV-2 immunity assessments requires a more nuanced analysis of the immune response, since a significant number of SARS-CoV-2 positive individuals have not developed any discernable antibody counts post-infection.  

A Solution for Improved SARS-CoV-2 Immunity Assessing
Attana Virus Analytics - AVA™ is a generic IVD device for non-clinical laboratory use, consisting of Attana's proprietary third-generation biosensor, various assays, and reagents. This technology enables AVA™ to take a broader approach when assessing immunity compared with the most prevalent virus diagnostics tools that are traditional based on ELSIA assays. By comparing an individual's immune responses in a series of tests, a full patient immunity profile can be established and manifested. The AVA™ platform could therefore provide invaluable insights on an individual patient level, as well as the most suitable vaccination programmes based on the population's immunity.

Nest steps for AVA™ platform
Although Attana recently entered the IVD market, our biosensor instruments have been used by Big Pharma, biotech companies, and academia for over 18 years and been highlighted in over 130 peer-reviewed publications. Attana have recently initiated a regulatory approval process for the AVA™ platform and will continue to engage in cross-disciplinary development of a point-of-care IVD device with AI-enabled automated analytic capabilities.    

Read the full article here (https://issuu.com/mark123/docs/2020-covid-supplement-2-web_compres_0adc0150a61177/18).